Quabodepistat clinical trials
How each study uses quabodepistat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the quabodepistat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Otsuka Pharmaceutical Development & Commercialization, Inc. (5) · University College, London (1)
Often tested with
Tested in the same studies.
OPC-67683 (2) · Bedaquiline (2) · Moxifloxacin (2) · Ganfeborole (1) · BTZ-043 (1) · Pretomanid (1) · Linezolid (1) · Pyrazinamide (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test quabodepistat.
- Feb 2027Platform Assessing Regimens and Durations In a Global Multisite Consortium for TBPhase 2 · University College, London
Studies
Open first, then newest update. How each study uses quabodepistat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary TuberculosisRecruitingPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07209761Written as Quabodepistat
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TBRecruitingPhase 2University College, LondonNCT06114628Written as Quabodepistat (Q)
- Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TBCompletedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05221502Written as OPC-167832 10 mg
- A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and WomenCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07542847Written as OPC-167832
- A Study to Detect Radioactivity of [14C]-OPC-167832 in Urine and Feces in Healthy MenCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07314320Written as [14C]-OPC-167832
- A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary TuberculosisCompletedPhase 1/2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT03678688Written as 10 mg OPC-167832
Given beside what is tested · 1 — quabodepistat is usual care or a partner of the new treatment
Codes
What other systems call quabodepistat · ClinicalTrials.gg INT014342
- UNII (FDA) 1PQN78P4S3QUABODEPISTATOne source FDA
- NCI Thesaurus C188494QuabodepistatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 1PQN78P4S3 | QUABODEPISTAT | One source FDA |
| NCI Thesaurus | C188494 | Quabodepistat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.